Loading
A phase 2 trial of nimotuzumab and gemcitabine + nab-paclitaxel in pancreatic cancer, run by The First Affiliated Hospital with Nanjing Medical University, not yet recruiting.
Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer is a phase 2, randomised interventional study registered as NCT07277452 by The First Affiliated Hospital with Nanjing Medical University, with a registry enrolment figure of 156 participants, started 2025-12-10 and due to reach its primary completion in 2028-12-10. Interventions recorded: Nimotuzumab; AG regimen; Placebo. Conditions listed: Pancreatic Cancer, Adult. Primary outcome: disease-free survival (DFS). Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC);". Sites: China. No results are recorded here; the registry entry is the source.
Shares Gemcitabine + nab-paclitaxel, Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Nimotuzumab, Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Gemcitabine + nab-paclitaxel, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Nimotuzumab, Gemcitabine + nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Gemcitabine + nab-paclitaxel, Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Nimotuzumab, Gemcitabine + nab-paclitaxel, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Nimotuzumab, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Nimotuzumab, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.